>> 全站文章索引 >> 第39页:
  • Ageing and neuronal vulnerability - [Mattson MP, Magnus T.]
  • Rational Antidepressant Selection：Applying Evidence-Based Medicineto Complex Real-World Patients - [Zetin M, Hoepner CT, Bjornson L]
  • Rational Antidepressant Selection-Applying Evidence-Based Medicine to Complex Real-World Patients - [Zetin M, Hoepner CT, Bjornson L.]
  • Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine - [Vered Stearns, Michael D. Johnson, James M. Rae, Alan Morocho, Antonella Novielli, Pankaj Bhargava, Daniel F. Hayes,]
  • Relationship of Mania Symptomatology to Maintenance Treatment Response with Divalproex, Lithium, or Placebo - [Charles L Bowden1, Michelle A Collins2, Susan L McElroy3, Joseph R Calabrese4, Alan C Swann5, Richard H Weisler6,7 and Patricia J Wozniak2]
  • Aging, estradiol and time of day differentially affect serotonin transporter binding in the central nervous system of female rats - [Kristine Krajnak, Katherine L. Rosewell, Marilyn J. Duncan and Phyllis M. Wise]
  • Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety - [Sandy Hogg, Line Michan and Maria Jessa]
  • Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. - [Kennedy SH, Andersen HF, Lam RW]
  • Acute SSRI Administration Affects the Processing of Social Cues in Healthy Volunteers - [C J Harmer1, Z Bhagwagar1, D I Perrett2, B A V?llm1, P J Cowen1 and G M Goodwin1]
  • Rapid response of emotional incontinence to selective serotonin reuptake inhibitors - [Nahas Z, Arlinghaus KA, Kotrla KJ, Clearman RR, George MS]
  • Electroanalytical determination of paroxetine in pharmaceuticals - [Henri P.A. Nouws, Cristina Delerue-Matos, Aquiles A. Barros and José A. Rodrigues]
  • The effects of antidepressants on obstructed and unobstructed gait in healthy elderly people - [Louis F Draganich, James Zacny, Jerome Klafta, Theodore Karrison]
  • Accelerating response in geriatric depression: A pilot study combining sleep deprivation and paroxetine - [Gregory M. Bump, M.S. 1, Charles F. Reynolds III, M.D. 1 *, Gwenn Smith, Ph.D. 1, Bruce G. Pollock, M.D., Ph.D. 1, Mary Amanda Dew, Ph.D. 1, Sati Mazumdar, Ph.D. 1, Matthew Geary, B.A. 1, Patricia R. Houck, M.S.H. 1, David J. Kupfer, M.D. 2 AD:1Mental Hea]
  • Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly - [Gregory M. Bump, M.D., Benoit H. Mulsant, M.D., Bruce G. Pollock, M.D., Ph.D., Sati Mazumdar, Ph.D., Amy E. Begley, M.A., Mary Amanda Dew, Ph.D., Charles F. Reynolds III, M.D. * AD:Intervention Research Center for Late-Life Mood Disorders, Department of P]
  • Acute angle closure glaucoma associated with paroxetine - [T Eke, A K Bates, S Carr]
  • Differential effects of tumor necrosis factor-alpha co-administered with amyloid beta-peptide (25–35) on memory function and hippocampal damage in rat - [Stepanichev M, Zdobnova I, Zarubenko I, Lazareva N, Gulyaeva NV.]
  • Early adversity and alcohol availability persistently modify serotonin and hypothalamic–pituitary–adrenal-axis metabolism and related behavior:What experimental research on rodents and primates can tell us - [Macrì S, Spinelli S, Adriani W, Dee Higley J, Laviola G.]
  • A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes - [Paola Rocca, Livio Marchiaro, Roberta Rasetti, Elisa Rivoira and Filippo Bogetto]
  • Predictors of nonresponse to treatment in primary care patients with dysthymia - [Wayne Katon, Joan Russo, Ellen Frank, James Barrett, John W. Williams, Thomas Oxman, Mark Sullivan and John Cornell]
  • Respiratory irregularity and stress hormones in panic disorder exploring potential linkages - [Abelson JL, Khan S, Lyubkin M, Giardino N.]
  • Respiratory irregularity and stress hormones in panic disorder exploring potential linkages - [Abelson JL, Khan S, Lyubkin M, Giardino N.]
  • Depression after stroke - [Castillo, Carlos S.; Robinson, Robert G.]
  • Therapeutic potential of RNA interference for neurological disorders - [Sah DW.]
  • Assessment of the Serotonin and Norepinephrine Reuptake Blocking Properties of Duloxetine in Healthy Subjects - [Julie E Turcotte MD, Guy Debonnel MD, Claude de Montigny MD, Ph.D, Chantal Hébert RN and Pierre Blier MD, Ph.D]
  • Double-blind placebo-controlled pilot study of paroxetine for specific phobia - [J. Benjamin, I. Z. Ben-Zion, E. Karbofsky, P. Dannon]
  • THE RISE AND RISE OF DRUG DELIVERY - [Howard Rosen & Thierry Abribat about the authors]
  • Withdrawal from paroxetine can be severe, warns FDA - [Alison Tonks]
  • Disease mongering and drug marketing - [Howard Wolinsky]
  • Validation of [123I]-CIT SPECT to Assess Serotonin Transporters In Vivo in Humans: a Double-Blind, Placebo-Controlled, Crossover Study with the Selective Serotonin Reuptake Inhibitor Citalopram - [Maartje M L de Win1,2, Jan B A Habraken3, Liesbeth Reneman1, Wim van den Brink4, Gerard J den Heeten1 and Jan Booij3]
  • What has dry cough in common with pruritus? Treatment of dry cough with paroxetine - [Zbigniew Zylicz and Magorzata Krajnik]
  • SENSORY FILTERING PHENOMENOLOGY IN PTSD - [Stewart LP, White PM.]
  • SENSORY FILTERING PHENOMENOLOGY IN PTSD - [Stewart LP, White PM.]
  • Bipolar (Spectrum) Disorder and Mood Stabilization Standing at the Crossroads - [De Fruyt J, Demyttenaere K.]
  • The effect of depression on quality of life of patients with type II diabetes mellitus - [Eren I, Erdi O, Sahin M.]
  • Quantitative 1H NMR method for the routine spectroscopic determination of enantiomeric purity of active pharmaceutical ingredients fenfluramine, sertraline, and paroxetine - [Jonathon S. Salsbury *, Paul K. Isbester AD:Albany Molecular Research, Incorporation, Albany, NY 12212-5098, USA]
  • Diminished Sexual Activity, Interest, and Feelings of Attractiveness Among HIV-Infected Women in Two Eras of the AIDS Epidemic - [Siegel K, Schrimshaw EW, Lekas HM.]
  • Genome-wide linkage scan of 98 bipolar pedigrees and analysis of clinical covariates - [Zandi PP, Badner JA, Steele J, Willour VL, Miao K, MacKinnon DF, Mondimore FM, Schweizer B, McInnis MG, DePaulo JR, Gershon E, McMahon FJ, Potash JB.]
  • The biological treatment of dangerous sexual offenders: A review and preliminary report of the Oregon pilot depo-Provera program - [Barry M. Maletzky and Gary Field]
  • Hormonal markers of stress response following interruption of selective serotonin reuptake inhibitor treatment - [David Michelson, Jay Amsterdam, Jeffrey Apter, Maurizio Fava, Peter Londborg, Roy Tamura and Lisa Pagh]
  • Extrapyramidal symptoms and antidepressant drugs: neuropharmacological aspects of a frequent interaction in the elderly - [S Govoni1, M Racchi1, E Masoero1, M Zamboni2 and L Ferini-Strambi2]
  • The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression - [Dorotea Mück-eler, Nela Pivac, Marina agud, Miro Jakovljevi and Alma Mihaljevi-Pele]
  • Prognosis of Patients Taking Selective Serotonin Reuptake Inhibitors Before Coronary Artery Bypass Grafting - [Glen L. Xiong, Wei Jiang, Robert Clare, Linda K. Shaw, Peter K. Smith, Kenneth W. Mahaffey, Christopher M. O’Connor, K. Ranga R. Krishnan and L. Kristin Newby]
  • Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression - [Sidney H Kennedy, Kenneth P Evans, Stephanie Kruger, Helen S Mayberg, et al]
  • The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review - [S Williams1 and J Dale1]
  • Therapeutic effects of milnacipran, a serotonin and noradrenaline reuptake inhibitor, on post-stroke depression - [Kimura, M. a.; Kanetani, K. b.; Imai, R. c.; Suzuki, H. a.; Isayama, K. b.; Endo, S. a.]
  • Major depression with ischemic heart disease effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. - [Yeragani VK, Roose S, Mallavarapu M, Radhakrishna RK, Pesce V.]
  • Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. - [Yeragani VK, Roose S, Mallavarapu M, Radhakrishna RK, Pesce V]
  • Treatment of mood disorders - [Charles B. Nemeroff & Michael J. Owens]
  • Dementia of Depression in Parkinson's Disease and Stroke - [STARKSTEIN, S. EEGIO; ROBINSON, R. OBERT]
  • Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype - [Catherine Heurteaux, Guillaume Lucas, Nicolas Guy, Malika El Yacoubi, Susanne Th??mmler, Xiao-Dong Peng, Florence Noble, Nicolas Blondeau, Catherine Widmann, Marc Borsotto, Gabriella Gobbi, Jean-Marie Vaugeois, Guy Debonnel, Michel Lazdunski]
  • Tolerability of paroxetine in Parkinson's disease: A prospective study - [Silvana Tesei, MD, Angelo Antonini, MD *, Margherita Canesi, MD, Anna Zecchinelli, MD, Claudio B. Mariani, MD, Gianni Pezzoli, MD AD:Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy]
  • Depression rating scales in Parkinson's disease Critique and recommendations - [Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, Weintraub D, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG.]
  • Effect of SSRI antidepressants on ejaculation a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. - [Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B.]
  • A Systematic Review of Antidepressant Placebo-Controlled Trials for Geriatric Depression: Limitations of Current Data and Directions for the Future - [Warren D Taylor and P Murali Doraiswamy]
  • Depression in older adults exploring the relationship between goal setting and physical health - [Street H, O]
  • Depression in older adults- exploring the relationship between goal setting and physical health - [Street H, O]
  • Serotonin 1A Receptor Binding and Treatment Response in Late-Life Depression - [Carolyn Cidis Meltzer1,2,3, Julie C Price1, Chester A Mathis1, Meryl A Butters2, Scott K Ziolko1, Eydie Moses-Kolko2, Sati Mazumdar2,4, Benoit H Mulsant2, Patricia R Houck2, Brian J Lopresti1, Lisa A Weissfeld4 and Charles F Reynolds2,3,5]
  • Influence of menstrual cycle on platelet serotonin uptake site and serotonin2A receptor binding - [Anna-Carin Wihlb?ck, Inger Sundstr?m Poromaa, Marie Bixo, Per Allard, Tom Mj?rndal and Olav Spigset]
  • Managing rapid metabolizers of antidepressants - [Robert P. Kraus, F.R.C.P.C. *, Paula Diaz, B.Sc. (Hons), M.R. Pharm. S., L.H.S.C., Andrea McEachran, B.A. (Hons), L.H.S.C. AD:Department of Psychiatry, London Health Sciences Centre, Victoria Campus, London, Ontario, Canada]
  • Antidepressants augment natural killer cell activity: in vivo and in vitro. - [Frank MG, Hendricks SE, Johnson DR, Wieseler JL, Burke WJ]
  • Depression and breastfeeding-which postpartum patients take antidepressant medications - [Battle CL, Zlotnick C, Pearlstein T, Miller IW, Howard M, Salisbury A, Stroud L.]
  • Interaction of somatoform and vestibular disorders - [Best C, Eckhardt-Henn A, Diener G, Bense S, Breuer P, Dieterich M.]
  • Chronic paroxetine infusion influences macronutrient selection in male Sprague–Dawley rats - [A. T. M. Konkle, K. B. Sreter, S. L. Baker and C. Bielajew]
  • Paroxetine binding in aggressive schizophrenic patients - [I. Modai, A. Gibel, B. Rauchverger, M. Ritsner, E. Klein and D. Ben Shachar 348.]
  • Paroxetine binding in aggressive schizophrenic patients - [Ilan Modai, Anatoly Gibel, Boris Rauchverger, Michael Ritsner, Ehud Klein and Dorit Ben-Shachar]
  • Comorbidity of panic and depression implications for clinical management - [Ballenger JC.]
  • Therapeutic advances: Paroxetine for the treatment of social anxiety disorder - [R. Bruce Lydiard, Ph.D., M.D. 1 *, Julio Bobes 2 AD:1Department of Psychiatry, Medical University of South Carolina, Charleston, South Carolina2Facultad de Medicina, Universidad de Oviedo, Spain]
  • The Neurotoxic Effects of 3,4-Methylenedioxymethamphetamine (MDMA) and Methamphetamine on Serotonin, Dopamine, and GABA-ergic Terminals: An In-Vitro Autoradiographic Study In Rats - [Brian D. Armstrong and Kevin K. Noguchi]
  • Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy - [L Capuron1,2, A Ravaud3, P J Neveu1, A H Miller2, M Maes4 and R Dantzer1]
  • Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity - [M Ingelman-Sundberg1]
  • Serotonin-Mediated Cyclic AMP Inhibitory Pathway in Platelets of Patients - [Liliana Dell]
  • The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care - [Centre for the Economics of Mental Health, Health Services Research Department, Institute of Psychiatry, King]
  • Norepinephrine but not Serotonin Reuptake Inhibitors Enhance Theta and Gamma Activity of the Septo-Hippocampal System - [Mihály Hajós1, William E Hoffmann1, Deborah D Robinson2, Jen H Yu2 and éva Hajós-Korcsok2]
  • Verdict on clinical trials registries? Good, but must do better - [Meredith Wadman]
  • How well do antidepressants work in older people? A systematic review of Number Needed to Treat - [Katona C, Livingston G..]
  • Advances in oral therapy for multiple myeloma - [Morgan GJ, Krishnan B, Jenner M, Davies FE.]
  • Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care a randomized trial - [Kroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R, Stang P, Zhou XH, Hays R, Weinberger M.]
  • Treatment of dysthymia and minor depression in primary care A randomized controlled trial - [Williams JW, Barrett J, Oxman T, Frank E, Katon W, Sullivan M, Cornell J, Sengupta A.]
  • Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults.[see comment] - [Ambulatory Care (11C-6), 7400 Merton Minter Blvd, San Antonio, TX 78284, USA. jwilliam@verdict.uthscsa.edu]
  • The next happy pill - [Les Iversen]
  • The endocrine system and ageing - [Chahal HS, Drake WM.]
  • The challenge of depression in late life: Bridging science and service in primary care - [Gallo JJ, Coyne JC]
  • Diagnosing Depression After Stroke - [BLACK, K. EVIN]
  • Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine - [Robert D. Nebes, Bruce G. Pollock, Patricia R. Houck, Meryl A. Butters, Benoit H. Mulsant, Michelle D. Zmuda and Charles F. Reynolds]
  • Cocaine-associated stroke: three cases and rehabilitation considerations - [Raj D. Tolat, Michael W. O]
  • Sulpiride in Combination with Fluvoxamine Increases in vivo Dopamine Release Selectively in Rat Prefrontal Cortex - [Yukio Ago1, Shigeo Nakamura1, Akemichi Baba2 and Toshio Matsuda1]
  • Evaluation of the effect of chronic antidepressant treatment on neurokinin-1 receptor expression in the rat brain - [S. B. Sartori, P. W. J. Burnet, T. Sharp and N. Singewald]
  • Clinical trial data: to disclose or not to disclose? - [Aaron Bouchie]
  • Differential effects of simultaneous or sequential administration of paroxetine and WAY-100,635 on ejaculatory behavior - [C. Looney, K.B. Thor, D. Ricca and L. Marson]
  • Dopaminergic mechanism of antidepressant action in depressed patients - [Paul Willner, Anthony S. Hale and Spilios Argyropoulos]
  • Do mood disorders alter crying a pilot investigation - [Rottenberg J, Cevaal A, Vingerhoets AJ.]
  • Effects of chronic paroxetine pretreatment on (±)-8-hydroxy-2-(di-n-propyl-amino)tetralin induced c-fos expression following sexual behavior - [T.R. de Jong, T. Pattij, J.G. Veening, P.J.W.C. Dederen, M.D. Waldinger, A.R. Cools and B. Olivier]
  • Paroxetine alters KCl- or ATP-induced contractile responses of isolated vas deferens in rats chronically treated with ethanol - [Murat Kesim, Mine Kadioglu, Ersin Yaris, Nuri Ihsan Kalyoncu, Rasin Ozyavuz and Cunay Ulku]
  • Alterations in serotonin transporter expression in brain regions of rats exposed neonatally to chlorpyrifos - [Kimberly W. Raines, Frederic J. Seidler and T. A. Slotkin]
  • Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment - [M. Bixo, P. Allard, T. B?ckstr?m, T. Mj?rndal, S. Nyberg, O. Spigset and I. Sundstr?m-Poromaa]
  • Withdrawal symptoms from paroxetine - [Colin Milliken 1, Stephen J. Cooper 2 * AD:1Department of Psychiatry, Belfast City Hospital, Belfast, UK2Department of Mental Health, The Queen]
  • Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors - [Centorrino, Franca, Baldessarini, Ross J, et al]
  • Cancer pain and its impact on diagnosis, survival and quality of life - [Mantyh PW.]
  • Effect of acute and chronic administration of caffeine on pain-like behaviors in rats with partial sciatic nerve injury - [Wu WP, Hao JX, Fredholm BB, Wiesenfeld-Hallin Z, Xu XJ.]
  • Modification of presynaptic CaM kinase II affinity for ATP in hippocampus after long term blockade of serotonin reuptake - [Elena Consogno, Cinzia Dorigo, Giorgio Racagni and Maurizio Popoli]


    • 分页: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 [39] 40
    41 42 43 44 45 46 47 48 49 50